HC Wainwright Has Pessimistic Outlook of Myomo Q1 Earnings

Myomo, Inc. (NYSEAMERICAN:MYO) – Research analysts at HC Wainwright dropped their Q1 2026 EPS estimates for Myomo in a research note issued to investors on Tuesday, March 10th. HC Wainwright analyst S. Lee now anticipates that the company will post earnings of ($0.11) per share for the quarter, down from their prior forecast of ($0.10). The consensus estimate for Myomo’s current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Myomo’s Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.34) EPS, FY2027 earnings at ($0.22) EPS, FY2028 earnings at ($0.05) EPS and FY2029 earnings at $0.16 EPS.

MYO has been the topic of a number of other research reports. Craig Hallum reiterated a “buy” rating on shares of Myomo in a research note on Tuesday. Ascendiant Capital Markets dropped their price objective on Myomo from $10.50 to $10.00 and set a “buy” rating on the stock in a research note on Friday, November 21st. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $7.67.

Myomo Stock Down 3.7%

MYO stock opened at $0.69 on Thursday. Myomo has a 52 week low of $0.64 and a 52 week high of $5.62. The company has a market capitalization of $26.50 million, a price-to-earnings ratio of -1.86 and a beta of 1.17. The firm’s 50-day moving average is $0.85 and its two-hundred day moving average is $0.92. The company has a current ratio of 3.30, a quick ratio of 2.10 and a debt-to-equity ratio of 0.98.

Hedge Funds Weigh In On Myomo

Hedge funds have recently modified their holdings of the stock. Bank of America Corp DE lifted its holdings in shares of Myomo by 93.6% during the third quarter. Bank of America Corp DE now owns 30,412 shares of the company’s stock valued at $27,000 after purchasing an additional 14,705 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Myomo by 103.1% during the fourth quarter. Wells Fargo & Company MN now owns 38,707 shares of the company’s stock valued at $35,000 after buying an additional 19,646 shares in the last quarter. Invesco Ltd. acquired a new position in shares of Myomo in the second quarter worth about $37,000. Intech Investment Management LLC purchased a new position in shares of Myomo in the second quarter worth approximately $38,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Myomo during the second quarter valued at approximately $38,000. 44.99% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Heather C. Getz purchased 70,000 shares of the company’s stock in a transaction on Thursday, March 12th. The shares were bought at an average price of $0.73 per share, with a total value of $51,100.00. Following the completion of the acquisition, the director owned 111,754 shares of the company’s stock, valued at approximately $81,580.42. This represents a 167.65% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 4.79% of the company’s stock.

Myomo News Summary

Here are the key news stories impacting Myomo this week:

• Positive Sentiment: Director Heather C. Getz bought 70,000 shares at an average price of $0.73 on March 12, increasing her stake by ~167.7%. Insider buying can signal management confidence in the business and is often viewed positively by investors. SEC filing
• Neutral Sentiment: Q4 2025 earnings call highlighted record revenue but also rising expenses — revenue strength is encouraging for growth expectations, but higher costs and margin pressure temper the near-term outlook. This mixed operational update helps explain investor caution. Earnings Call Highlights
• Neutral Sentiment: HC Wainwright published a long‑range FY2030 estimate of $0.35 EPS, indicating they still see long‑term profitability potential, which could support speculative investor interest if execution improves.
• Negative Sentiment: HC Wainwright cut near- and medium-term EPS estimates across Q1–Q3 2026 and FY2026–FY2029 (including lowering FY2026 to ($0.34) from ($0.31) and trimming FY2029 to $0.16 from $0.30). Revisions reduce near-term profitability expectations and can pressure the stock and investor sentiment.
• Negative Sentiment: Myomo added a forward‑looking disclosure flagging elevated risk around reimbursement, financing and growth plans — an explicit risk warning can amplify investor wariness about execution and cash needs. Risk Disclosure Article

About Myomo

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.